Akili is building clinically validated cognitive therapeutics, assessments and diagnostics that look and feel like high-quality video games. Leveraging medical-grade science and consumer-grade software technology, the company is seeking to produce a new type of healthcare product that is both highly-effective and highly-engaging. The company was founded by PureTech Health, together with leading neuroscientists and game designers. Akili has garnered investment from Shire PLC and has strategic partnerships with Pfizer Inc. and Autism Speaks.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/22/16 | $30,500,000 |
Canepa Advanced Healthcare Fund Jazz Venture Partners | undisclosed | |
| 07/20/16 | $11,900,000 | Series B Extension |
Amgen Business Development Merck Ventures | undisclosed |
| 05/09/18 | $55,000,000 | Series C |
Amgen Business Development Baillie Gifford Brooklands Capital Strategies Canepa Advanced Healthcare Fund Jazz Venture Partners M Ventures Temasek  | undisclosed |
| 05/26/21 | $110,000,000 | Series D |
Baillie Gifford Dave Baszucki Evidity Health Capital Jazz Venture Partners Ladera Venture Partners Mirae Asset Venture Investment Neuberger Berman New Leaf Venture Partners Polaris Partners QUAD Investment Management Shionogi & Co. Temasek | undisclosed |
